
Promising viral gene therapy for genetic kidney disease
UK resesearchers have engineered an adeno-associated virus vector to treat the heriditary steroid-resistant nephrotic syndrome in children, which is...

Oxford Biomedica expands agreement with Cabaletta Bio
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients...

Evotec earns US$40m in global licence deal with BMS
Under a potential US$4bn iPSC-based drug discovery partnership in neurodegeneration with Evotec SE, originally signed in 2016 through Celgene,...

Spexis AG bags money for pivotal Phase III trial
The cash injection of US$2.5m that was led by SPRIM Global Investments (SGI) is urgently needed to finance US commercialisation of the company’s...

PureTech Health gets US$11.4m to advance LYT-300
PureTech Health plc has been awarded up to $11.4 million from the US government to advance LYT-300 (oral allopregnanolone) for the treatment of...

BioSenic halts ALLOB development
ALLOB was developed before the US$40.8m majority buyout of Bone Therapeutics by French Medsenic SAS last October. Before the reverse merger, in...

Nanobiotix SA licences NBTXR3 to J&J
NBTXR3 is currently being evaluated across different solid tumour indications including NANORAY‑312, a global Phase III pivotal study in ...